BioCryst Pharmaceuticals, Inc. (BCRX)
Largest Insider Buys in Sector
BCRX Stock Price History Chart
BCRX Stock Performance
About BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 …
Insider Activity of BioCryst Pharmaceuticals, Inc.
Over the last 12 months, insiders at BioCryst Pharmaceuticals, Inc. have bought $1.05M and sold $176,191 worth of BioCryst Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at BioCryst Pharmaceuticals, Inc. have bought $673,474 and sold $4.18M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Thackray Helen M. (Chief R&D Officer) — $351,600. Doyle Anthony (Chief Financial Officer) — $202,191. Stonehouse Jon P (President & CEO) — $166,500.
The last purchase of 7,861 shares for transaction amount of $49,996 was made by LEVIN ALAN G (director) on 2024‑05‑30.
List of Insider Buy and Sell Transactions, BioCryst Pharmaceuticals, Inc.
| 2024-12-13 | Sale | director | 7,000 0.0034% | $7.54 | $52,780 | -0.53% | ||
| 2024-06-24 | Sale | director | 8,600 0.0042% | $6.32 | $54,352 | +21.53% | ||
| 2024-06-17 | Sale | director | 4,689 0.0021% | $6.00 | $28,134 | +21.79% | ||
| 2024-06-14 | Sale | director | 6,698 0.0031% | $6.11 | $40,925 | +23.18% | ||
| 2024-05-30 | director | 7,861 0.0037% | $6.36 | $49,996 | +14.92% | |||
| 2024-05-24 | director | 2,500 0.0012% | $6.40 | $16,000 | +22.76% | |||
| 2024-05-20 | director | 5,000 0.0025% | $6.38 | $31,900 | +22.79% | |||
| 2024-05-20 | director | 15,000 0.0074% | $6.25 | $93,750 | +22.79% | |||
| 2024-05-14 | Chief R&D Officer | 30,000 0.0159% | $5.86 | $175,800 | +40.19% | |||
| 2024-05-14 | Chief Financial Officer | 36,300 0.0183% | $5.57 | $202,191 | +40.19% | |||
| 2024-05-13 | President & CEO | 30,000 0.0143% | $5.55 | $166,500 | +32.98% | |||
| 2024-05-13 | Chief Commercial Officer | 30,000 0.0141% | $5.47 | $164,100 | +32.98% | |||
| 2024-05-13 | Chief Legal Officer | 5,000 0.0024% | $5.53 | $27,650 | +32.98% | |||
| 2024-05-13 | director | 21,940 0.0104% | $5.49 | $120,451 | +32.98% | |||
| 2023-06-15 | Sale | director | 4,000 0.0021% | $7.98 | $31,920 | -24.59% | ||
| 2023-06-14 | Sale | director | 12,866 0.0069% | $8.04 | $103,443 | -24.06% | ||
| 2023-04-03 | Sale | Chief R&D Officer | 7,000 0.0037% | $8.29 | $58,030 | -19.09% | ||
| 2023-02-01 | Sale | President & CEO | 100,000 0.0523% | $10.38 | $1.04M | -31.89% | ||
| 2022-12-15 | Sale | President & CEO | 14,100 0.0079% | $10.90 | $153,690 | -30.48% | ||
| 2022-12-15 | Sale | Chief Commercial Officer | 6,100 0.0034% | $10.90 | $66,490 | -30.48% |
Insider Historical Profitability
| Stonehouse Jon P | President & CEO | 1127770 0.5445% | $7.57 | 14 | 8 | +33.26% |
| Gayer Charles K | Chief Commercial Officer | 307533 0.1485% | $7.57 | 1 | 1 | |
| Barnes Alane P | Chief Legal Officer | 300762 0.1452% | $7.57 | 2 | 8 | +118.24% |
| Thackray Helen M. | Chief R&D Officer | 272139 0.1314% | $7.57 | 1 | 3 | |
| Doyle Anthony | Chief Financial Officer | 266744 0.1288% | $7.57 | 3 | 1 | +77.54% |
Institutional Investor Ownership
| BlackRock | $93.68M | 8.94 | 18.44M | -1.29% | -$1.22M | <0.01 | |
| The Vanguard Group | $89.8M | 8.57 | 17.68M | -0.49% | -$441,721.24 | <0.01 | |
| State Street | $88.78M | 8.47 | 17.48M | +36.79% | +$23.88M | <0.01 | |
| Avoro Capital Advisors Llc | $66.29M | 6.32 | 13.05M | 0% | +$0 | 0.79 | |
| Baker Bros Advisors LP | $51.44M | 4.91 | 10.13M | 0% | +$0 | 0.37 |